Relative Versus Absolute Noncontagiousness of Respiratory Tuberculosis on Treatment

Infection Control and Hospital Epidemiology

Volumn 24, Issue 11, 2003, Pages 831-838

  Long, Richard ^a,c   Bochar, Karen ^a   Chomyc, Sylvia ^a   Talbot, James ^a   Barrie, James ^a   Kunimoto, Dennis ^a   Tilley, Peter ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIUM CULTURE; CANADA; CLINICAL ARTICLE; COMPARATIVE STUDY; DISEASE COURSE; DNA FINGERPRINTING; DNA PROBE; FEMALE; HUMAN; ISOLATION AND PURIFICATION; LUNG TUBERCULOSIS; MALE; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; PATHOLOGY; RESPIRATORY TRACT INFECTION; RISK FACTOR; SPUTUM; SPUTUM SMEAR; TIME; TUBERCULOSIS; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADULT; ALBERTA; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; DISEASE PROGRESSION; FEMALE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; RISK FACTORS; SPUTUM; TIME FACTORS; TUBERCULOSIS, PULMONARY;

EID: 0345169915     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/502145     Document Type: Article

References (54)

1. Shaw JB, Wynn-Williams N. Infectivity of pulmonary tuberculosis in relation to sputum status. Am Rev Tuberc 1954;69:724-732.
2. Grzybowski S, Allen E. The challenge of tuberculosis in decline. Am Rev Respir Dis 1964;90:707-720.
3. Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: the effects of chemotherapy. Tubercle 1976;57:275-299.
4. Sepkowitz KA. How contagious is tuberculosis? Clin Infect Dis 1996;23:954-962.
5. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities. MMWR 1994;43(RR-13):1-132.
6. Horsburgh RC Jr, Feldman S, Ridzon R. Practice guidelines for the treatment of tuberculosis. Clin Infect Dis 2000;31:633-639.
7. Menzies D, Conly J. Tuberculosis control in Canadian health care institutions. In: Long R, ed. The Canadian Tuberculosis Standards, 5th ed. Ottawa: Health Canada and the Canadian Lung Association; 2000:207-221.
8. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998;53:536-538.
9. Yeager H Jr, Lacy J, Smith LR, LeMaistre CA. Quantitative studies of mycobacterial populations in sputum and saliva. Am Rev Respir Dis 1967;95:998-1004.
10. Kim TC, Blackman RS, Heatwole KM, Kim T, Rochester DF. Acid-fast bacilli in sputum smears of patients with pulmonary tuberculosis. Am Rev Respir Dis 1984;129:264-268.
11. Telzak EE, Fazal BA, Pollard CL, Turett GS, Justman JE, Blum S. Factors influencing time to sputum smear conversion among patients with smear-positive pulmonary tuberculosis. Clin Infect Dis 1997;25:666-670.
12. Hasegawa N, Miura T, Ishizaka A, Yamaguchi K, Ishii K. Detection of mycobacteria in patients with pulmonary tuberculosis undergoing chemotherapy using MGIT and egg-based solid medium culture systems. Int J Tuberc Lung Dis 2002;6:447-453.
13. Bass JB Jr, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359-1374.
14. Long R, Zielinski M, Kunimoto K, Manfreda J. The emergency department is a determinant point of contact of tuberculosis patients prior to diagnosis. Int J Tuberc Lung Dis 2002;6:332-339.
15. Falk A, O'Connor JB, Pratt PC, Webb WR, Wier JA, Wolinsky E. Classification of pulmonary tuberculosis. In: Diagnostic Standards and Classification of Tuberculosis, 12th ed. New York: National Tuberculosis and Respiratory Disease Association; 1969:68-76.
16. Hawkins JE, Karlson AG, Wayne LG. Quality of laboratory services for mycobacterial diseases: official statement of the American Thoracic Society. Am Rev Respir Dis 1974;110;376-377.
17. Marks J, Thomas CCH. Notes on the cultivation of tubercle bacilli. In: Monthly Bulletin: Minnesota Health, Public Health Laboratory Service, vol. 17. Minnesota Health, Public Health Laboratory; 1958.
18. Marks J. A system for examination of tubercle bacilli and other mycobacteria. Tubercle 1976;57;207-225.
19. Zaher F, Marks J. Methods and medium for the cultivation of the tubercle bacilli. Tubercle 1977;58:143-145.
20. Pfyffer GE, Welscher H-M, Kissling P, et al. Comparison of the Mycobacteria Growth Indicator Tube (MGIT) with radiometric and solid culture for recovery of acid-fast bacilli. J Clin Microbiol 1997;35:364-368.
21. Long R, Chui L, Kakulphimp J, Zielinski M, Talbot J, Kunimoto D. Postsanatorium pattern of antituberculous drug resistance in the Canadian-born population of western Canada: effect of outpatient care and immigration. Am J Epidemiol 2001;153:903-911.
22. Epstein MD, Schluger NW, Davidow AL, Bonk SB, Rom WN, Hanna B. Time to detection of M. tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest 1998;113:379-386.
23. Altman DG. Practical Statistics for Medical Research. London: Chapman and Hall; 1991.
24. Curry FJ. The effect of acceptable and adequate outpatient treatment on the length of hospitalization and on readmission for relapse or reactivation of pulmonary tuberculosis. Chest 1973;63:536-546.
25. East African/British Medical Research Councils. Controlled clinical trial of four short-course (6 month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1973;1:1331-1338.
26. Dufour G. Mycobacteriology. Seminars in Pediatric Infectious Diseases 1993;4:205-213.
27. Krasnow I, Wayne LG. Sputum digestion: I. The mortality rate of tubercle bacilli in various digestive systems. Am J Clin Pathol 1966;45:352-355.
28. Kent PT, Kubica GP. Public Health Mycobacteriology: A Guide to the Level III Laboratory. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention; 1985.
29. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121:939-949.
30. Hobby GL, Holman AP, Iseman MD, Jones J. Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis. Antimicrob Agents Chemother 1973;4:94-104.
31. Wallis RS, Patil S, Cheon S-H, et al. Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999;43:2600-2606.
32. Wells WF. Airborne Contagion and Airborne Hygiene: An Ecological Study of Droplet Infection. Cambridge, MA: Harvard University Press; 1955.
33. Riley RL, Mills CC, Nyka W, et al. Aerial dissemination of tuberculosis: a two year study of contagion in a tuberculosis ward. American Journal of Hygiene 1959;70:185-196.
34. Sultan I, Nyka W, Mills C, O'Grady F, Wells W, Riley RL. Tuberculosis disseminators: a study of the variability of aerial infectivity of tuberculosis patients. Am Rev Respir Dis 1960;82:358-369.
35. Riley RL, Mills CC, O'Grady F, Sultan LU, Wittestadt F, Shivipuri DN. Infectiousness of air from a tuberculosis ward-ultraviolet irradiation of infected air: comparative infectiousness of different patients. Am Rev Respir Dis 1962;85:511-525.
36. Loudon RG, Roberts RM. Droplet expulsion from the respiratory tract. Am Rev Respir Dis 1967;95:435-442.
37. Snider DE Jr, Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis 1985;132:125-132.
38. Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bulletin of the International Union Against Tuberculosis 1975;50:90-106.
39. Behr M, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999;353:444-449.
40. Menzies D. Effect of treatment on contagiousness of patients with active pulmonary tuberculosis. Infect Control Hosp Epidemiol 1997;18:582-586.
41. Catanzaro A. Nosocomial tuberculosis. Am Rev Respir Dis 1982;125:559-562.
42. Di Perri G, Danzi MC, De Checchi G, et al. Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet 1989;2:1502-1504.
43. Dunlap NE, Bass J, Fujiwara P, et al. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161:1376-1395.
44. Loudon RG, Romans WE. Cough frequency and infectivity in patients with pulmonary tuberculosis. Am Rev Respir Dis 1969;99:109-111.
45. Hopewell PC. Factors influencing the transmission and infectivity of Mycobacterium tuberculosis: implications for clinical and public health management. In: Sande MA, Hudson LD, Root RK, eds. Respiratory Infections. New York: Churchill Livingstone; 1986:191-216.
46. Kamat SR, Dawson JJY, Devadatta S, et al. A controlled study of the influence of segregation of tuberculosis patients for one year on the attack rate of tuberculosis in a 5 year period in close family contacts in south India. Bull World Health Organ 1966;34:517-532.
47. Brooks SM, Lassiter NL, Young EC. A pilot study concerning the infection risk of sputum positive tuberculosis patients on chemotherapy. Am Rev Respir Dis 1973;108:799-804.
48. Abeles H. Early hospital discharge of tuberculosis patients with sputum containing acid-fast bacilli on microscopic examination. Am Rev Respir Dis 1973;108:975-977.
49. Gunnels JJ, Bates JH, Swindoll H. Infectivity of sputum positive patients on chemotherapy. Am Rev Respir Dis 1974;109:323-330.
50. Riley RL, Moodie AS. Infectivity of patients with pulmonary tuberculosis in inner city homes. Am Rev Respir Dis 1974;110:810-812.
51. Noble RC. Infectiousness of pulmonary tuberculosis after starting chemotherapy. Am J Infect Control 1981;9:6-10.
52. Subbaiah IV, Bhatia AL, Geraghty E, Mitchison DA, Radhakrishna S, Selkon JB. The virulence in the guinea-pig of isoniazid-sensitive tubercle bacilli isolated from South India patients before treatment and after three months of treatment. Bull World Health Organ 1961;25:759-764.
53. Loudon RG, Bumgarner LR, Coffman GK. Isoniazid and the survival of tubercle bacilli in airborne droplet nuclei. Am Rev Respir Dis 1969;100:172-176.
54. Clancy LJ, Kelly P, O'Reilly L, Byrne C, Costello E. The pathogenicity of Mycobacterium tuberculosis during chemotherapy. Eur Respir J 1990;3:399-402.